Cronos Group (CRON) Lifted to C+ at TheStreet

Cronos Group (NASDAQ:CRON) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c+” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.

Other equities analysts also recently issued reports about the stock. CIBC set a $30.00 target price on shares of Cronos Group and gave the company a “buy” rating in a report on Wednesday, March 27th. Zacks Investment Research upgraded shares of Cronos Group from a “strong sell” rating to a “hold” rating in a report on Friday, May 10th. GMP Securities downgraded shares of Cronos Group from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. They noted that the move was a valuation call. Eight Capital downgraded shares of Cronos Group to a “hold” rating in a report on Thursday, March 7th. Finally, Cowen began coverage on shares of Cronos Group in a report on Tuesday, March 5th. They set a “market perform” rating for the company. Five equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $17.03.

NASDAQ:CRON opened at $15.24 on Tuesday. Cronos Group has a twelve month low of $5.61 and a twelve month high of $25.10. The stock has a market cap of $5.04 billion, a price-to-earnings ratio of -190.50 and a beta of 3.84.



Cronos Group (NASDAQ:CRON) last posted its earnings results on Thursday, May 9th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.38. Cronos Group had a net margin of 2,107.83% and a return on equity of 99.44%. The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $6.87 million. Cronos Group’s revenue for the quarter was up 119.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Cronos Group will post -0.04 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. RPG Investment Advisory LLC grew its holdings in shares of Cronos Group by 237.5% during the first quarter. RPG Investment Advisory LLC now owns 1,350 shares of the company’s stock worth $25,000 after buying an additional 950 shares in the last quarter. Oakworth Capital Inc. purchased a new stake in shares of Cronos Group during the first quarter worth about $30,000. Kistler Tiffany Companies LLC grew its holdings in shares of Cronos Group by 125.0% during the first quarter. Kistler Tiffany Companies LLC now owns 1,755 shares of the company’s stock worth $32,000 after buying an additional 975 shares in the last quarter. Focused Wealth Management Inc grew its holdings in shares of Cronos Group by 48.5% during the first quarter. Focused Wealth Management Inc now owns 1,849 shares of the company’s stock worth $34,000 after buying an additional 604 shares in the last quarter. Finally, Whitnell & Co. purchased a new stake in shares of Cronos Group during the first quarter worth about $35,000. Institutional investors and hedge funds own 5.58% of the company’s stock.

Cronos Group Company Profile

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada.

Read More: Why is a lock-up period needed for an IPO?

Analyst Recommendations for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.